<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Novel N-glycosylation sites are introduced by <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> into the V genes of the majority of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Sites are positively selected and rare in <z:mpath ids='MPATH_458'>normal</z:mpath> memory B cells, indicating a potential role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> survival in the germinal centre (GC) </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of c </plain></SENT>
<SENT sid="3" pm="."><plain>40% in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) parallels the known <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the disease </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002721'>Immunodeficiency</z:hpo>-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) include post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) and acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome-related NHL (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-NHL) </plain></SENT>
<SENT sid="5" pm="."><plain>Most PTLD derive from B cells that carry mutated VH genes and that have completed the GC reaction </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-NHL carry mutated VH genes and variable features of GC or post-GC cells </plain></SENT>
<SENT sid="7" pm="."><plain>To determine if N-glycosylation is a feature of <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, we analysed the VH genes of 19 PTLD and 36 AIDS-NHL </plain></SENT>
<SENT sid="8" pm="."><plain>Novel sites were rare in PTLD (4/19), similar to memory B cells (P = 0.15) </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-NHL, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), showed <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> with 16 of 36 (44%) having novel sites </plain></SENT>
<SENT sid="10" pm="."><plain>The findings indicate no selection of N-glycosylation sites in PTLD, consistent with post-GC features </plain></SENT>
<SENT sid="11" pm="."><plain>The variable incidence of N-glycosylation sites in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-NHL mirrors that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> of immunocompetent hosts, supporting the known <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of these disorders, and possibly pointing to distinct routes of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
</text></document>